Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC
SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO,Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'. The total contract size is325 million dollar...
2023-05-31 13:02
1461
Sorrento Announces Definitive Agreements for up to $150 Million Private Placement
SAN DIEGO, April 5, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs company, today announced that it has entered into definitive agreements with instit...
2016-04-05 08:55
3145
